Ser381
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser381  -  NIPA (human)

Site Information
RTRPVTRsMGtGDtP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 14576869

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 1 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 9 ) , mutation of modification site ( 1 )
Disease tissue studied:
breast cancer ( 3 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , lymphoma ( 1 ) , anaplastic large cell lymphoma ( 1 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 9 ) , BaF3 ('B lymphocyte, precursor') ( 1 ) , Calu 6 (pulmonary) ( 5 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 2 , 4 , 8 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 3 ) , HMLER ('stem, breast cancer') ( 3 ) , JB-6 (lymphocyte) ( 1 ) , Jurkat (T lymphocyte) ( 7 ) , K562 (erythroid) ( 4 ) , MEF (fibroblast) ( 1 ) , NCI-H1648 (pulmonary) ( 5 ) , TS (lymphocyte) ( 1 )

Upstream Regulation
Regulatory protein:
NPM-ALK (human) ( 1 )

Downstream Regulation
Effects of modification on NIPA:
intracellular localization ( 1 ) , molecular association, regulation ( 1 )
Effects of modification on biological processes:
cell growth, induced ( 1 )
Inhibit interaction with:
NPM-ALK (human) ( 1 )

References 

1

Gengenbacher A, et al. (2019) Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues. Int J Mol Sci 20
31434245   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

4

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

5

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

6

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

7

Guo A (2011) CST Curation Set: 12024; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

8

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

9

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.